202 results about "Toxoplasma gondii" patented technology

The invention relates to the technical field of biology, in particular to an antigen chip used for detecting human parasites antigens in serum and a preparation method thereof. The invention spots antigen array of parasites which are seriously harmful to human body, Schistosoma, Lung fluke, Clonorchis sinensis, Cysticercosis, Sparganum mansoni, Trichina, Angiostrongylus cantonensis, Toxoplasma gondii, and the like, on a solid phase membrane carrier, and specific gamma immunoglobulin (IgG) of human parasites in serum is detected by a specially made vertical flow chip detect device, and the detecting marker is colloid gold second antibody conjugate or colloid gold protein A conjugate of fresh color. IgG antibodies in serum specially bind with the antigens on the membrane in percolation process layer upon layer, and human IgG which specially binds with the antigens is detected by the colloid gold marker. Detecting of a plurality of parasites antigen indexes in serum sample can be finished within several minutes. The device and the method have the advantages of high throughput, simple operation, convenient use and being suitable for parasitic diseases clinical test and serum-epidemiological investigation.

This invention relates to a method for treatment of latent Toxoplasma gondii infection. The invention provides for the use of Hsp90 inhibitors for treatment of latent Toxoplasma gondii infection, particularly in an immunocompromised subject. Also provided is a screening method for identifying compounds useful for treating latent Toxoplasma gondii infection.

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula,

wherein the variables X, Y, Z, L, R¹, and R³ are defined herein.

The present invention presents a method of preventing vertical transmission of an infectious disease comprising: (a) applying a photosensitizing composition to host tissues of birth canal of a mother during the intrapartum period; and (b) applying light to the host tissues after the step (a) at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate infectious disease microorganisms that come into contact with the host tissues. The infectious disease may be caused by human immunodeficiency virus type 1, hepatitis B virus, hepatitis C virus, Group B Streptococcus, cytomegalovirus, Listeria monocytogenes, Chiamydia trachomatis, Escherichia coli, herpes simplex virus, Epstein-Barr virus, Toxoplasma gondii, human papilloma virus, and Candida.

The invention provides a Toxoplasma colloidal gold immunochromatographic test strip, comprising a sample pad, a colloidal gold binding pad, a detection line, a quality control line and a water-absorbing material which are arranged sequentially along a sample flowing direction, wherein the detection line includes a toxoplasma specific antigen. The Toxoplasma colloidal gold immunochromatographic test strip allows Toxoplasma in human and various mammals to be quickly detected in simple and easy way.

A reagent kit based on recombinant antigen for detecting Toxoplasma is prepared through taking 542-1218 fragment (t SAG1) from the primary surface antigen gene SAG1 of Toxoplasma, subcloning it to soluble expression carrier pET32a(+), transferring it to colibacillus, configuring engineering bacterium pET32a-tSAG1/BL21, IPTG induced efficient expression, ultrasonic splitting to obtain supernatant, purifying by Ni-NTA and Sephadex-G75, and coating the microholes on ELISA plate. Its test paper can also be prepared by same way.

The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.

The invention discloses a preparation method of a fluorescent marker gene chip reagent which can be used for simultaneously detecting ToRCH, namely five pathogens such as toxopasma, rubella virus, cytomegalo virus and pure herpes virus type I/II. Compared with the prior art, the preparation method has the characteristics of high specificity, high sensitivity and short operation time, and therefore, the preparation method has broad application prospect. In addition, the invention provides the reagent obtained by the preparation method and a kit used for the detection method.

The invention discloses a screening method of small-molecule inhibitor capable of inhibiting proliferation of toxoplasma gondii. The method utilizes an Alphascreen experiment to primarily select 11 small-molecule inhibitors and one small-molecule accelerant, and the 12 drugs are used for clinical treatment. The 12 drugs are further screened at the cellular level, a plaque experiment proves that GSK J4HCL apparently inhibits the proliferation of toxoplasma gondii, and the value EC50 of the GSK J4HCL to toxoplasmagondii is determined to be about 4.5 muM by virtue of intracellular proliferation experiment. The AlphaScreen competitive inhibition experiment evaluates that the value IC50 of the GSK J4HCL for inhibiting the interaction of TgAtg8 to TgAtg3 is 11.01 muM. The CCK8 experiment is usedfor proving that the value IC50 of the drug for inhibiting the growth of a host cell is 34.359 muM which is far greater than the value EC50 of the drug for the insect, which illustrates that the GSKJ4HCL is a low-toxicity and high-efficiency drug for resisting the toxoplasma gondii.

The invention provides a method for studying differentially expressed proteome in brain tissues of mice chronically infected with toxoplasma gondii by an iTRAQ (Isobaric Tags For Relative And Absolute Quantitation) technology. The invention also provides a protein or polypeptide interacting with developmentally regulated brain protein and application of the protein or polypeptide. In the invention, six toxoplasma gondii proteins interacting with the developmentally regulated brain protein are found by CoIP and Pulldown experiments; and gene knockout experiments and neurobehavioral validation are further performed on TgRPS14 gene and TgH4 gene. The method for studying differentially expressed proteome in brain tissues of mice chronically infected with toxoplasma gondii provided by the invention can rapidly and effectively perform proteomics research, and is beneficial for rapidly positioning to detection targets and prevention and treatment medicine target points with a research value or a commercial application value.

The invention discloses a PCR detection reagent box of animal toxoplasmosis; the box contains DNA lysate, red blood cell lysate, white blood cell lysate, PCR reaction liquid and toxoplasmosis gene DNA positive control liquid; the 529bp repeated DNA segment of toxoplasmin is taken as genetic mark and special primer is taken to optimize the PCR reaction conditions such as the magnesium ion consistency, the anneal temperature and the regulation of the cycle number. The invention can detect the toxoplasmosis infection of pig, dog and cat in a fast special sensible way; the operation is convenient and the sensibility is high; the invention can be used for diagnosing the toxoplasmosis of pig, dog and cat and detecting and testing the drug effect appraisal of the selection of the toxoplasmosis medicines.

The invention discloses a fluorescent quantitative PCR (FQ-PCR) kit for rapidly detecting Toxoplasma gondii, relating to gene detection technology of zoonosis pathogen, and being applicable to qualitative and quantitative detection of Toxoplasma gondii. The invention comprises DNA extracting solution, a standard positive template, a fluorescent quantitative PCR reaction solution, Toxoplasma gondii B1 gene specific primer and a negative quality control standard product. The invention is accurate in quantifying, rapid in detection speed, good in specificity, high in sensitivity, simple in use steps and high in repeatability and can replace traditional etiology detection method.

The invention relates to immunity gold mark quick testing reagent which measures the toxoplasma antibody and the preparative method thereof. One end of a PVC back lining is orderly stuck with a sample mat, a combination mat, a phroxylin film, and a sopping mat. The combination mat is wrapped with antigenic colloid gold combos metabolized and excreted by the toxoplasma, the top of the phroxylin film is wrapped with antigen metabolized and excreted by toxoplasma and toxoplasma antibodies. Through toxoplasma metabolizing antigen, preparing toxoplasma antibody, preparing colloid gold, preparing toxoplasma metabolizing and excreting antigen colloid gold mark craftworks, finally the toxoplasma metabolizing and excreting antigen colloid gold mark is wrapped on the colloid gold combination mat to wrap the toxoplasma metabolizing and excreting antigen and toxoplasma antibody in the measuring district and the sluggish control district in a line shape to produce the reagent. The invention with strong specificity, high sensitivity, simple operation, quick ability and cheap price is applicable to the filed measuring, the whole process only needs 20 minutes, the operators need not be professionally trained and the operation following the instruction can be fulfilled.

The invention discloses health-care wine used for dispelling toxoplasma gondii and a preparation method thereof. The health-care wine used for dispelling toxoplasma gondii is characterized by being prepared from, by weight, 1-3 parts of Chinese herbal extract powder and 7-9 parts of wine, wherein the Chinese herbal extract powder is prepared from 1-3 parts of chrysanthemums, 2-5 parts of rhizoma polygonati, 1-3 parts of Chinese wolfberry fruit, 1-3 parts of dandelions and 1-4 parts of oysters, the chrysanthemums, the rhizoma polygonati, the Chinese wolfberry fruit, the dandelions, the oysters and the wine are taken in proportion, water with the weight 5 times that of the chrysanthemums, the rhizoma polygonati, the Chinese wolfberry fruit, the dandelions and the oysters is added, soaking is performed for 12 h after boiling, leach liquor is obtained, drying and powder spraying are performed after the leach liquor is concentrated into thick paste through filtering and pressure reduction, then the mixture is added into the wine and stirred to be fully dissolved, supernatant is obtained after standing lasts for 24 h, and the health-care wine used for dispelling toxoplasma gondii is obtained. The health-care wine can be used for effectively dispelling toxoplasma gondii, and meanwhile the physique and the immunity of human bodies are enhanced.

Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.

The invention discloses a GRA17 gene deleted toxoplasma gondii attenuative mutant strain. The GRA17 gene deleted toxoplasma gondii attenuative mutant strain is LZdeltaGRA17, which is preserved in China Center for Type Culture Collection with a preservation number of CCTCC NO:V201656. The invention also provides a preparation method of the strain. According to the invention, the GRA17 gene deleted toxoplasma gondii attenuative mutant strain provided by the invention is established on a molecular biology basis, and is a gene deleted insect strain constructed based on the CRISPR/Cas9 gene knockout technology, the insect strain has attenuated toxicity, also loses the biological characteristic of lethality to mice, has enormous application value, and can be used as a candidate strain of attenuated live vaccines.

A rapid detection reagent of a toxoplasma circulating antigen immune colloidal gold marker comprises a sample pad, a bonding pad, a cellulose nitrate film, a water absorbent pad and a PVC back lining, wherein, one end of the PVC back lining is sequentially adhered with the sample pad, the bonding pad, the cellulose nitrate film and the water absorbent pad, the bonding pad is coated by a colloidal gold bonder with an anti-toxoplasma polyclonal antibody, the anti-toxoplasma polyclonal antibody and a toxoplasma metaboly secrete antigen are linearly coated on the cellulose nitrate film. The toxoplasma circulating antigen immune colloidal gold marker rapid detection reagent is prepared by preparing the anti-toxoplasma polyclonal antibody, preparing the toxoplasma metaboly secrete antigen, preparing the colloidal gold, preparing a colloidal gold marker of the anti-toxoplasma polyclonal antibody; the colloidal gold marker of the anti-toxoplasma polyclonal antibody is coated on the colloidal gold bonding pad, the anti-toxoplasma polyclonal antibody and the toxoplasma metaboly secrete antigen are linearly coated in a detection region and a stagnant control region of the cellulose nitrate film and the thorough drying and other processes are carried out. The rapid detection reagent of the toxoplasma circulating antigen immune colloidal gold marker can detect the toxoplasma circulating antigens of people and various animals, which has accurate sensitivity and simple operation, and being safe and stable.

The invention provides a vaccine for preventing toxoplasma infection. The vaccine contains nucleotide sequences selected from the followings: 1) 736-2385th nucleotide sequences as shown in SEQ ID No.1, and/or 759-2411th nucleotide sequences as shown in SEQ ID No.3; 2) nucleotide sequences complementary with the nucleotide sequences as shown in 1); and 3) nucleotide sequences which perform substituting, deletion and addition modification on one or a plurality of basic groups of the nucleotide sequences as shown in 1) or 2). The vaccine has the capability of effectively preventing and controlling the infection of a toxoplasma animal model (Kunming mice), and the combination of recombinant plasmids can effectively improve the immune effect of a single-gene vaccine, therefore, plasmids pVAX-ROP5 and pVAX-GRA15 can be used as DNA (Deoxyribose Nucleic Acid) vaccine candidate antigens for preventing the toxoplasma infection; and a combined immune vaccine of a recombinant plasmid based on such two genes can be used as a cocktail composite vaccine for preventing the toxoplasma infection.

The invention discloses an attenuated live vaccine for preventing the infection of toxoplasma gondii and application of the attenuated live vaccine. The attenuated live vaccine is a toxoplasma gondii attenuated strain PRU delta CDPK2 tachyzoite suspension prepared by adopting PBS as a solvent. An immune dosage form of the attenuated live vaccine is determined, an immune inoculation program and an inoculation amount of the vaccine are ascertained, the attenuated live vaccine has higher immunity protection effect for the acute infection, chronic infection and congenital infection of the toxoplasma gondii by virtue of an animal experiment, not only can prevent the normal infection of the toxoplasma gondii, but also can effectively prevent the vertical propagation of the toxoplasma gondii by virtue of a mother-infant route, is attenuated live vaccine with great application value, can be used for preventing the chronic infection, acute infection and congenital infection of the toxoplasma gondii, and can effectively prevent the toxoplasma gondii.